Hospital
Peacehealth
Peacehealth was paid $47.27M by Medicaid between Jan 2018 and Dec 2024, across 365 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 19% of everything it billed.
33Billing provider infoPEACEHEALTH
BELLINGHAM, WA 98225
BELLINGHAM, WA 98225
33aNPI1487904546assigned 09/17/2012
33bProvider typePsychiatric Hospital Unit
28Total paid$47.27M
24GClaims1,679,596
24DCodes billed365
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Washington
Rank by total paid#3 of 11
Median peer was paid$15K
This provider vs. median3,226×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SEIRER, JEFFREY controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 220,906 | $5.71M | |
| 2019 | 215,584 | $5.95M | |
| 2020 | 211,035 | $6.13M | |
| 2021 | 251,907 | $7.27M | |
| 2022 | 266,247 | $8.12M | |
| 2023 | 275,988 | $7.66M | |
| 2024incomplete | 237,929 | $6.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 19% | 32,038 | 26,294 | $8.90M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 44,362 | 41,015 | $5.07M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.4% | 73,110 | 49,829 | $3.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 45,501 | 41,569 | $3.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 54,115 | 48,194 | $2.93M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 11,210 | 10,632 | $1.79M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 17,398 | 12,881 | $1.54M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 10,468 | 9,914 | $1.36M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.7% | 7,722 | 4,743 | $1.29M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.5% | 5,980 | 5,871 | $1.20M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 10,454 | 9,848 | $1.12M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 9,288 | 8,061 | $1.05M |
353 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 28,156 | $744K |
| 87631 | 1.5% | 12,896 | $694K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 2,244 | $635K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 30,320 | $625K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 3,692 | $565K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 5,567 | $561K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,581 | $391K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,219 | $379K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,759 | $359K |
| 80053 | Comprehensive metabolic panel | <1% | 86,476 | $354K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 17,999 | $319K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,981 | $316K |
| 12001 | <1% | 1,608 | $306K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 115 | $285K |
| 96415 | <1% | 1,434 | $279K | |
| 10060 | <1% | 1,644 | $277K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,174 | $251K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,581 | $224K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,072 | $222K |
| 93017 | <1% | 3,297 | $220K | |
| 95886 | <1% | 1,401 | $216K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,282 | $200K |
| 93971 | <1% | 2,393 | $177K | |
| 93321 | <1% | 1,275 | $174K | |
| 12002 | <1% | 976 | $169K | |
| 70496 | <1% | 1,176 | $168K | |
| 96367 | <1% | 4,595 | $160K | |
| 12011 | <1% | 705 | $159K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 9,118 | $148K |
| 97162 | <1% | 3,992 | $147K | |
| G0378 | Hospital observation service, per hour | <1% | 8,333 | $133K |
| 64615 | <1% | 532 | $133K | |
| 97161 | <1% | 3,552 | $127K | |
| 84484 | <1% | 34,896 | $122K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,885 | $114K |
| 44970 | <1% | 39 | $110K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,828 | $109K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,322 | $108K |
| 76830 | Ultrasound, transvaginal | <1% | 1,427 | $107K |
| 93458 | <1% | 108 | $99K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,900 | $96K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 17,884 | $95K |
| 97113 | <1% | 2,318 | $90K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,329 | $80K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 668 | $71K |
| 93970 | <1% | 858 | $68K | |
| 83605 | <1% | 12,143 | $67K | |
| 95819 | <1% | 361 | $59K | |
| 20610 | <1% | 608 | $59K | |
| 29125 | <1% | 425 | $58K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,822 | $57K |
| 76801 | <1% | 1,346 | $55K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 334 | $49K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 120 | $47K |
| 90715 | <1% | 2,877 | $47K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 44,046 | $46K |
| 97165 | <1% | 1,414 | $46K | |
| 93325 | <1% | 1,642 | $44K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,367 | $44K |
| 29581 | <1% | 482 | $42K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,806 | $41K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 157 | $40K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,023 | $37K |
| 97116 | <1% | 3,641 | $37K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,438 | $35K |
| 93922 | <1% | 955 | $34K | |
| 85379 | <1% | 7,842 | $34K | |
| 70491 | <1% | 178 | $33K | |
| 36430 | <1% | 317 | $33K | |
| 87040 | <1% | 4,126 | $31K | |
| 97597 | <1% | 1,110 | $31K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 169 | $30K |
| 47563 | <1% | 13 | $29K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,757 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 374 | $28K |
| 93246 | <1% | 1,010 | $27K | |
| 83880 | <1% | 7,271 | $27K | |
| 70498 | <1% | 1,237 | $26K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 94,346 | $26K |
| 77336 | <1% | 471 | $24K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,373 | $22K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,905 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 34,629 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 97,886 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,204 | $20K |
| 93798 | <1% | 3,043 | $20K | |
| 93880 | <1% | 423 | $20K | |
| 70486 | <1% | 830 | $18K | |
| 93308 | <1% | 77 | $17K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 865 | $16K |
| 97163 | <1% | 359 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,413 | $16K |
| 96416 | <1% | 46 | $15K | |
| 93976 | <1% | 1,007 | $15K | |
| 87486 | <1% | 1,879 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 19,770 | $12K |
| 97166 | <1% | 331 | $11K | |
| 93225 | <1% | 342 | $10K | |
| 96368 | <1% | 2,079 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,053 | $9K |
| 76870 | <1% | 102 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 34,606 | $8K |
| 87581 | <1% | 1,884 | $7K | |
| 85610 | <1% | 18,243 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,155 | $6K |
| 83735 | <1% | 23,505 | $6K | |
| 84703 | <1% | 23,097 | $6K | |
| 93296 | <1% | 985 | $6K | |
| 93242 | <1% | 185 | $6K | |
| 80305 | <1% | 10,222 | $6K | |
| 76770 | <1% | 62 | $6K | |
| 88307 | <1% | 420 | $5K | |
| 0296T | <1% | 326 | $5K | |
| 74230 | <1% | 86 | $5K | |
| 93226 | <1% | 290 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 45 | $5K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,248 | $5K |
| 92526 | <1% | 241 | $5K | |
| 77334 | <1% | 65 | $5K | |
| 83690 | <1% | 30,967 | $4K | |
| 77300 | <1% | 102 | $4K | |
| 73610 | <1% | 2,487 | $4K | |
| 93271 | <1% | 64 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 229 | $4K |
| 76937 | <1% | 100 | $4K | |
| 86923 | <1% | 219 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,407 | $4K |
| 73130 | <1% | 2,102 | $4K | |
| 81001 | <1% | 33,271 | $3K | |
| 76942 | <1% | 210 | $3K | |
| 86850 | <1% | 3,318 | $3K | |
| 43235 | <1% | 12 | $3K | |
| 85027 | <1% | 5,178 | $3K | |
| 87420 | <1% | 162 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,497 | $3K |
| 96376 | <1% | 13,748 | $3K | |
| 93797 | <1% | 796 | $3K | |
| 97760 | <1% | 141 | $3K | |
| 73630 | <1% | 2,218 | $3K | |
| 73560 | <1% | 2,463 | $3K | |
| 29075 | <1% | 14 | $3K | |
| 95911 | <1% | 168 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,332 | $2K |
| 93270 | <1% | 80 | $2K | |
| 73030 | <1% | 2,140 | $2K | |
| 10061 | <1% | 13 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 21 | $2K |
| 86900 | <1% | 3,465 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,318 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,292 | $2K |
| 95885 | <1% | 13 | $2K | |
| 84702 | <1% | 3,988 | $2K | |
| 73110 | <1% | 1,697 | $2K | |
| 97035 | <1% | 273 | $2K | |
| 82550 | <1% | 6,958 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $2K |
| 80061 | Lipid panel | <1% | 705 | $2K |
| 82728 | <1% | 1,394 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 123 | $2K |
| 86140 | <1% | 5,169 | $2K | |
| 84439 | <1% | 5,474 | $1K | |
| 74018 | <1% | 1,195 | $1K | |
| 86901 | <1% | 4,166 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,756 | $1K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 55 | $1K |
| 36591 | <1% | 175 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,374 | $1K |
| 73090 | <1% | 575 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,260 | $1K |
| 73080 | <1% | 873 | $1K | |
| 87205 | <1% | 3,428 | $1K | |
| 87147 | <1% | 3,112 | $1K | |
| 72100 | <1% | 1,117 | $1K | |
| 71250 | <1% | 39 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,375 | $1K |
| 90686 | <1% | 153 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,576 | $951.73 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,125 | $900.97 |
| 36600 | <1% | 1,383 | $891.69 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,538 | $865.63 |
| 95909 | <1% | 58 | $859.24 | |
| 87081 | <1% | 2,950 | $837.54 | |
| 82803 | <1% | 3,481 | $824.25 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 102 | $810.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,253 | $802.08 |
| 73502 | <1% | 985 | $775.13 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $764.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 18,357 | $753.43 |
| 80164 | <1% | 117 | $740.12 | |
| 72131 | <1% | 37 | $697.08 | |
| 76000 | <1% | 422 | $690.03 | |
| 87070 | <1% | 1,693 | $629.16 | |
| 96523 | <1% | 13 | $626.15 | |
| 93351 | <1% | 31 | $619.40 | |
| 73700 | <1% | 15 | $602.80 | |
| 73140 | <1% | 837 | $598.22 | |
| 93925 | <1% | 13 | $591.43 | |
| 87430 | <1% | 2,560 | $590.36 | |
| 85652 | <1% | 4,023 | $578.78 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,921 | $574.72 |
| 99152 | <1% | 1,449 | $564.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,247 | $559.98 |
| 85730 | <1% | 4,029 | $557.74 | |
| 84100 | <1% | 2,863 | $538.66 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 751 | $524.05 |
| 82075 | <1% | 1,755 | $519.92 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,462 | $512.50 |
| 87075 | <1% | 766 | $508.65 | |
| 88342 | <1% | 144 | $507.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,381 | $498.12 |
| 73590 | <1% | 918 | $487.27 | |
| 87186 | <1% | 4,041 | $483.33 | |
| 93280 | <1% | 106 | $470.11 | |
| C1769 | Guide wire | <1% | 2,334 | $409.98 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,075 | $388.30 |
| 74022 | <1% | 203 | $386.03 | |
| 96402 | <1% | 55 | $368.50 | |
| 87340 | <1% | 567 | $355.26 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,079 | $354.35 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,920 | $346.48 |
| 88304 | <1% | 1,131 | $342.31 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 170 | $339.21 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 562 | $333.42 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,375 | $326.22 |
| 86780 | <1% | 27 | $316.69 | |
| 85007 | <1% | 435 | $313.30 | |
| 87077 | <1% | 2,244 | $308.23 | |
| 83550 | <1% | 770 | $299.49 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 67 | $279.31 |
| 83540 | <1% | 850 | $274.61 | |
| 81025 | <1% | 1,911 | $250.53 | |
| 92610 | <1% | 12 | $249.60 | |
| 96417 | <1% | 1,218 | $235.87 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 612 | $234.80 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,001 | $232.91 |
| 82565 | <1% | 525 | $219.61 | |
| 87210 | <1% | 700 | $217.46 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,103 | $196.65 |
| 86803 | <1% | 363 | $195.47 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,809 | $186.24 |
| 89051 | <1% | 41 | $185.50 | |
| 87808 | <1% | 576 | $177.58 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,204 | $172.71 |
| 76376 | <1% | 1,054 | $163.67 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,640 | $159.02 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 63 | $145.00 |
| 82607 | <1% | 134 | $137.70 | |
| 81003 | <1% | 3,476 | $136.69 | |
| 90632 | <1% | 13 | $136.09 | |
| 82140 | <1% | 1,163 | $128.39 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,687 | $125.59 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 213 | $120.00 |
| 83615 | <1% | 125 | $116.97 | |
| 80178 | <1% | 13 | $113.67 | |
| A9270 | Non-covered item or service | <1% | 12,390 | $111.28 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15 | $106.93 |
| 82330 | <1% | 896 | $97.28 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,224 | $83.33 |
| Q3014 | Telehealth originating site facility fee | <1% | 79 | $81.04 |
| 82010 | <1% | 1,446 | $77.02 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,975 | $74.70 |
| 87088 | <1% | 949 | $69.58 | |
| 87899 | <1% | 287 | $62.35 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 344 | $58.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 2,048 | $54.06 |
| 36592 | <1% | 41 | $43.34 | |
| 72170 | <1% | 48 | $43.16 | |
| 86705 | <1% | 151 | $41.42 | |
| 72072 | <1% | 27 | $40.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,041 | $37.91 |
| 82746 | <1% | 38 | $37.60 | |
| 72040 | <1% | 53 | $37.27 | |
| 85014 | <1% | 60 | $32.23 | |
| 87045 | <1% | 120 | $31.04 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 815 | $30.23 |
| 86308 | <1% | 499 | $29.86 | |
| 87015 | <1% | 160 | $27.17 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 970 | $26.37 |
| 82570 | <1% | 261 | $25.69 | |
| 82378 | <1% | 20 | $25.14 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 743 | $23.77 |
| 84156 | <1% | 238 | $22.86 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,853 | $21.65 |
| 86709 | <1% | 78 | $20.93 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,925 | $19.56 |
| 87046 | <1% | 121 | $17.88 | |
| 87280 | <1% | 34 | $16.54 | |
| 87493 | <1% | 86 | $16.14 | |
| 85018 | <1% | 63 | $16.11 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 456 | $14.46 |
| 82247 | <1% | 45 | $13.86 | |
| 84550 | <1% | 153 | $13.55 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,139 | $12.52 |
| 73562 | <1% | 49 | $11.87 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 240 | $11.11 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 107 | $10.92 |
| 82040 | <1% | 17 | $9.94 | |
| 80306 | <1% | 282 | $9.15 | |
| 84450 | <1% | 16 | $8.60 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,445 | $5.33 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 318 | $3.74 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 756 | $1.01 |
| 51798 | 0% | 12 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 31 | $0.00 |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | 0% | 12 | $0.00 |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 0% | 94 | $0.00 |
| 71101 | 0% | 28 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 121 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 69 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 91 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 366 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 251 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 61 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 55 | $0.00 |
| 11045 | 0% | 22 | $0.00 | |
| 96411 | 0% | 41 | $0.00 | |
| 73660 | 0% | 16 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 26 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 13 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 70 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 83 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 15 | $0.00 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 40 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 747 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 229 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 870 | $0.00 |
| A4565 | Slings | 0% | 514 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 102 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 74 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 169 | $0.00 |
| 87150 | 0% | 112 | $0.00 | |
| 90662 | 0% | 24 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 58 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 51 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 269 | $0.00 |
| 96549 | 0% | 119 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 99 | $0.00 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 31 | $0.00 |
| 92611 | 0% | 13 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 125 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 55 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 13 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 13 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 39 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 28 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 373 | $0.00 |
| 74300 | 0% | 13 | $0.00 | |
| 84112 | 0% | 15 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 45 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 13 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSEIRER, JEFFREY (SYS VP FIN INTEGRITY/CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| Peacehealth | Vancouver, WA | $81.65M |
| Peacehealth | Longview, WA | $48.29M |
| Peacehealth | Springfield, OR | $30.72M |
| Peacehealth | Eugene, OR | $13.35M |
| Peacehealth | Vancouver, WA | $2.56M |
| Peacehealth | Eugene, OR | $1.84M |
| Peacehealth | Friday Harbor, WA | $1.06M |
| Peacehealth | Vancouver, WA | $1.00M |
| Peacehealth | Vancouver, WA | $814K |
| Peacehealth | Springfield, OR | $395K |
| Peacehealth | Bellingham, WA | $77K |
| Peacehealth | Kelso, WA | $13K |
| Peacehealth | Ketchikan, AK | $9K |
| Peacehealth | Eugene, OR | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.